How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/conbercept-ophthalmic-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Conbercept ophthalmic injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Conbercept ophthalmic injection (Conbercept ophthalmic injection) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF/PlGF inhibitor; recombinant fusion protein. Area: Ophthalmology.

phase 3 VEGF/PlGF inhibitor; recombinant fusion protein VEGF (vascular endothelial growth factor); PlGF (placental growth factor) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Conbercept ophthalmic injection (Conbercept ophthalmic injection) — Chengdu Kanghong Biotech Co., Ltd.. Conbercept is a recombinant fusion protein that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Conbercept ophthalmic injection TARGET	Conbercept ophthalmic injection	Chengdu Kanghong Biotech Co., Ltd.	phase 3	VEGF/PlGF inhibitor; recombinant fusion protein	VEGF (vascular endothelial growth factor); PlGF (placental growth factor)
conbercept, PRN	conbercept, PRN	Chengdu Kanghong Biotech Co., Ltd.	phase 3	VEGF/PlGF inhibitor (recombinant fusion protein)	VEGF (vascular endothelial growth factor) and PlGF (placental growth factor)
FYB206	FYB206	Formycon AG	phase 3	VEGF/PlGF inhibitor biosimilar	VEGF-A, VEGF-B, PlGF

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF/PlGF inhibitor; recombinant fusion protein class)

Chengdu Kanghong Biotech Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Conbercept ophthalmic injection — Competitive Intelligence Brief. https://druglandscape.com/ci/conbercept-ophthalmic-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing